Protein Sciences announces availability of Flublok influenza vaccine

Protein Sciences Corporation, the Meriden, Connecticut-based manufacturer of Flublok, announced on Wednesday that doses of the influenza vaccine for the 2013-2014 season are now available.

Flublok is a pure influenza vaccine that contains no preservatives, egg proteins, influenza virus, antibiotics, latex or gelatin. The U.S. Food and Drug Administration recently released the vaccine for the 2013-2014 season. Flublok is approved for individuals between the ages of 18 and 49 to prevent influenza disease.

Protein Sciences Corporation said that quantities of Flublok are limited and will be exclusively distributed by FFF Enterprises on a first-come, first-served basis.

Flublok is part of a new class of influenza vaccine called recombinant hemagglutinin influenza vaccine, trivalent formulation. RIV3s are produced by making just the active ingredient needed for protection against the flu virus without actually growing the virus itself. Protein Sciences Corporation said the vaccine contains three times more protective ingredient than the traditional flu vaccine.

The U.S. Centers for Disease Control and Prevention recommends the use of Flublok for all adults 18 to 49 years old, particularly individuals in the age range with a known or suspected egg allergy, regardless of the allergy's severity.

Flublok should not be given to individuals with a severe allergic reaction to any vaccine component.